Stockreport

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Definium Therapeutics, Inc. - Common Shares  (DFTX) 
PDF Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; top [Read more]